Comparison Overview

Astellas Pharma

VS

Servier

Astellas Pharma

2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo, JP, 103-8411
Last Update: 2026-01-18
View Profile
Between 750 and 799
http://www.astellas.com/

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,110
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Servier

50 rue Carnot, Suresnes, 92150, FR
Last Update: 2026-01-18
Between 750 and 799
https://servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 13,885
Subsidiaries: 2
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/astellaspharmainc.jpeg
Astellas Pharma
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/servier.jpeg
Servier
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Astellas Pharma
100%
Compliance Rate
0/4 Standards Verified
Servier
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Astellas Pharma in 2026.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Servier in 2026.

Incident History — Astellas Pharma (X = Date, Y = Severity)

Astellas Pharma cyber incidents detection timeline including parent company and subsidiaries

Incident History — Servier (X = Date, Y = Severity)

Servier cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/astellaspharmainc.jpeg
Astellas Pharma
Incidents

No Incident

https://images.rankiteo.com/companyimages/servier.jpeg
Servier
Incidents

No Incident

FAQ

Astellas Pharma company demonstrates a stronger AI Cybersecurity Score compared to Servier company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Servier company has disclosed a higher number of cyber incidents compared to Astellas Pharma company.

In the current year, Servier company and Astellas Pharma company have not reported any cyber incidents.

Neither Servier company nor Astellas Pharma company has reported experiencing a ransomware attack publicly.

Neither Servier company nor Astellas Pharma company has reported experiencing a data breach publicly.

Neither Servier company nor Astellas Pharma company has reported experiencing targeted cyberattacks publicly.

Neither Astellas Pharma company nor Servier company has reported experiencing or disclosing vulnerabilities publicly.

Neither Astellas Pharma nor Servier holds any compliance certifications.

Neither company holds any compliance certifications.

Servier company has more subsidiaries worldwide compared to Astellas Pharma company.

Servier company employs more people globally than Astellas Pharma company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Astellas Pharma nor Servier holds SOC 2 Type 1 certification.

Neither Astellas Pharma nor Servier holds SOC 2 Type 2 certification.

Neither Astellas Pharma nor Servier holds ISO 27001 certification.

Neither Astellas Pharma nor Servier holds PCI DSS certification.

Neither Astellas Pharma nor Servier holds HIPAA certification.

Neither Astellas Pharma nor Servier holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Typemill is a flat-file, Markdown-based CMS designed for informational documentation websites. A reflected Cross-Site Scripting (XSS) exists in the login error view template `login.twig` of versions 2.19.1 and below. The `username` value can be echoed back without proper contextual encoding when authentication fails. An attacker can execute script in the login page context. This issue has been fixed in version 2.19.2.

Published
Date
2026-01-23
Updated
Date
2026-01-23
Risk Information
cvss3
Base: 5.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:N
References
Description

A DOM-based Cross-Site Scripting (XSS) vulnerability exists in the DomainCheckerApp class within domain/script.js of Sourcecodester Domain Availability Checker v1.0. The vulnerability occurs because the application improperly handles user-supplied data in the createResultElement method by using the unsafe innerHTML property to render domain search results.

Published
Date
2026-01-23
Updated
Date
2026-01-23
References
Description

A Remote Code Execution (RCE) vulnerability exists in Sourcecodester Modern Image Gallery App v1.0 within the gallery/upload.php component. The application fails to properly validate uploaded file contents. Additionally, the application preserves the user-supplied file extension during the save process. This allows an unauthenticated attacker to upload arbitrary PHP code by spoofing the MIME type as an image, leading to full system compromise.

Published
Date
2026-01-23
Updated
Date
2026-01-23
References
Description

A UNIX symbolic link following issue in the jailer component in Firecracker version v1.13.1 and earlier and 1.14.0 on Linux may allow a local host user with write access to the pre-created jailer directories to overwrite arbitrary host files via a symlink attack during the initialization copy at jailer startup, if the jailer is executed with root privileges. To mitigate this issue, users should upgrade to version v1.13.2 or 1.14.1 or above.

Published
Date
2026-01-23
Updated
Date
2026-01-23
Risk Information
cvss3
Base: 6.0
Severity: LOW
CVSS:3.1/AV:L/AC:L/PR:H/UI:N/S:U/C:N/I:H/A:H
cvss4
Base: 6.0
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:N/SC:N/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

An information disclosure vulnerability exists in the /srvs/membersrv/getCashiers endpoint of the Aptsys gemscms backend platform thru 2025-05-28. This unauthenticated endpoint returns a list of cashier accounts, including names, email addresses, usernames, and passwords hashed using MD5. As MD5 is a broken cryptographic function, the hashes can be easily reversed using public tools, exposing user credentials in plaintext. This allows remote attackers to perform unauthorized logins and potentially gain access to sensitive POS operations or backend functions.

Published
Date
2026-01-23
Updated
Date
2026-01-23
References